Abstract: Disclosed is an SOMCL-9112 solid dispersion. The SOMCL-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of SOMCL-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer. Also disclosed are a preparation method of the SOMCL-9112 solid dispersion, a solid medicinal preparation containing the solid dispersion and application of the solid dispersion for preparing a medicine for treating cancer.

Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Also provided are methods of making the compounds of Formula (I) and their methods of use.

Abstract: The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comprising the compounds and the uses thereof as protein tyrosine kinase inhibitors, particularly as VEGFR-2 inhibitors, in preparing drugs for preventing and treating diseases related to abnormal angiogenesis.

Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Abstract: A unified content publishing system permits packaging and publishing of content items to multiple sites at once. Content items are grouped together using content groupings. A single content grouping may be assigned for publication through multiple sites. The content grouping may furthermore be assigned template data and layout data for generating a content package comprising information about the content items in the content grouping. To simplify publication, the template data and layout data may be used to publish the content grouping across all sites to which the content grouping has been assigned. Content packages may be manipulated across multiple sites simply by editing the content grouping, the assigned template data, and/or the assigned layout data. A construct referred to herein as a placeholder facilitates the above mappings. Subsites may be generated for different language profiles or other attributes, and placeholders may be pushed to all subsites having specified attributes.

Abstract: Approaches, techniques, and mechanisms are disclosed for the collection, distribution, and/or reporting of media content. According to an embodiment, media content items from one or more content providers are ingested into a content distribution system implemented by one or more server computer devices. These items of media content may comprise a variety of constituent elements, such as one or more video data units, one or more audio data units, descriptive metadata, subtitle units, thumbnails, or other information, which may be ingested all at once, or separately over time. Items may be processed using various workflows to refine content item components and/or generate new content items. Various publishing rules may be utilized to determine when the system is ready to publish a content item and distribute the item to client devices. Clients may request content items from various published listings, or search for content items by metadata and/or subtitles.

Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.

Abstract: The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.

Abstract: Disclosed is a method for processing downlink signalling of an SDN virtualization platform based on OpenFlow. The method comprises: after the preprocessing of downlink signalling is executed, further executing same, so as to judge whether more Match items also exist in a Match item list; if it is judged that more Match items also exist, acquiring an item from the Match item list; if it is judged that there are no more Match items, ending the processing; after completing the step of acquiring an item from the Match item list if it is judged that more Match items also exist, further judging whether more Action items also exist; if there are no more Action items, combining a new Action item list with the Match items to generate downlink signalling, and issuing same to a virtual network switch; and returning to the step to continue judging whether more Match items also exist; and if more Action items also exist, acquiring the next Action item.

Abstract: The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.

Abstract: A photovoltaic module comprises a back substrate having a plurality of conductive interconnects on top thereof. A conductive interconnect includes a first contact region and a second contact region. The photovoltaic module further comprises a plurality of photovoltaic cells comprising front electrodes disposed on a front surface of a photovoltaic layer on top of back electrodes on top of a support substrate. A plurality of back vias extending through the support substrate of a first cell form an electrical contact between the back electrodes and the second contact region, and a plurality of front vias extending through the support substrate, the back electrodes and the photovoltaic layer of a second cell form an electrical contact between the front electrodes and the first contact region, and is insulated from an electrical contact with the back electrodes and a P side of the photovoltaic layer.

Abstract: A method of fabricating an optoelectronic device includes the steps of providing a semiconductor unit and forming a plurality of metal contacts on a surface of the semiconductor unit for electrical conduction. The method further includes the step of forming a plurality of color coating regions on top of the plurality of metal contacts, the plurality of color coating regions imparting a color different than a color of the plurality of metal contacts.

Abstract: A method of preparing a biomarker functional validation array includes selecting one or more lists of candidate agents, predicting functions of the one or more lists of candidate agents and combining the predicted functions to yield a final list of functions to be validated, and generating a biomarker functional validation array including agents targeting the final list of functions.

Abstract: A method of identifying drug-drug, gene-drug or gene-gene interaction includes providing a plurality of arrays, each array including a plurality of ready-to-use plate wells, and each well including a bioactive material to target one or more cell component; adding a control and a candidate agent into the wells to form a control-material mix and an agent-material mix, respectively; when the control and the candidate agent are not cells, culturing a predetermined number of cells according to the number of the arrays and suspending and plating the cells into the arrays, when the control and the candidate agent are cells, no additional cells are needed; incubating the arrays in a cell culture incubator; measuring a predetermined signal; and collecting and analyzing data, thereby identifying the drug-drug, gene-drug, or gene-gene interaction.

Abstract: The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comprising the compounds and the uses thereof as protein tyrosine kinase inhibitors, particularly as VEGFR-2 inhibitors, in preparing drugs for preventing and treating diseases related to abnormal angiogenesis.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.

Abstract: Provided in the present invention are a 2-arylbenzofuran-7-formamide compound as shown in general formula I or a pharmacologically or physiologically acceptable salt thereof, a preparation method thereof and use thereof in preparing anti-tumour drugs, wherein R1 and R2 are each independently hydrogen, straight or branched chained C1-C4 alkyl, C3-C4 cycloalkyl or saturated 5- or 6-membered heterocyclyl containing oxygen or nitrogen; or R1 and R2 together with N form an unsubstituted or substituted saturated 5- or 6-membered heterocyclyl containing at least one heteroatom, wherein the heteroatom is O, N and S, the substituent is a methyl on N; R3 is a hydrogen atom or a chlorine atom; R4 is a hydrogen atom or a fluorine atom; X is CH, CF or N; and Y is CH, CF or N.

Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerising factor activity inhibitors and actin-aggregation inhibitors.

Abstract: The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.